Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brii BiosciencesFRA:7SS +2.78%33 EV-to-OCF is 4.39 as of Aug. 08, 2026, which is 60% above its 10-year median of 2.75. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Brii Biosciences ranks worse than 80.06% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Brii Biosciences's Enterprise Value is €-179.70 Mil.
Brii Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-40.97 Mil. Therefore, Brii Biosciences's EV-to-OCF for today is 4.39.
The historical rank and industry rank for Brii Biosciences's EV-to-OCF or its related term are showing as below:
FRA:7SS'
s EV-to-OCF Range Over the Past 10 Years
Min: -11.51 Med: 2.75 Max: 4.31
Current: 4.31
During the past 7 years, the highest EV-to-OCF of Brii Biosciences was 4.31. The lowest was -11.51. And the median was 2.75.
FRA:7SS's EV-to-OCF is ranked worse than 80.06% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs FRA:7SS: 4.31
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Brii Biosciences's PE Ratio (TTM) for today is calculated as:
Brii Biosciences's share price for today is €0.0925.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.037.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Brii Biosciences EV-to-OCF Related Terms
Brii Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Brii Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's EV-to-OCF falls into.
Brii Biosciences's current Enterprise Value is €-179.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-40.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences (FRA:7SS) has a EV-to-OCF of 4.39 as of Aug. 08, 2026. This is 60% above median its historical median of 2.75. According to the industry distribution chart, Brii Biosciences ranks #1128 out of 1409 companies in the Biotechnology industry, placing it in the top 80.1%.
Is Brii Biosciences' EV-to-OCF too high?
Brii Biosciences' current EV-to-OCF of 4.39 is 60% above median its 10-year median of 2.75. Based on the distribution chart, Brii Biosciences ranks #1128 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #1128 out of 1409 companies for EV-to-OCF. This places Brii Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Brii Biosciences's current EV-to-OCF is 4.39, which is 60% above median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current EV-to-OCF of 4.39. The current EV-to-OCF is 4.39, which is 60% above median its 10-year median of 2.75. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current EV-to-OCF is 4.39 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
